Chen Junyang, Xu Gaoxiang, Shen Runpu, Xu Jianzhong, Lu Congcong, Li Xin, Feng Qi, Li Qing
School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Adv Sci (Weinh). 2025 Jun;12(23):e2500026. doi: 10.1002/advs.202500026. Epub 2025 May 14.
This study have previously reported that ZIF-based chiral nanomedicines achieve Parkinson's disease (PD) therapy through differential metabolism and relief of neuroinflammation. However, lack of overall chirality and anti-inflammatory capacity of nanomedicines limit the further effective solution to the nanobiological effects research in PD. Here, it dexterously loaded chiral gold nanoclusters (AuNCs) onto the inner and outer surfaces of ZIF to achieve the purpose of simultaneously improving the overall chirality and anti-inflammatory activity of the composite nanoparticles (NPs). There are significant differences in the composition of protein corona between different chiral NPs, which elucidates the mechanism of chiral-mediated discrepancies in metabolism and the blood-brain barrier (BBB) traversing. Multi-omics and biochemical techniques further reveal that chiral NPs interfere with the chemokine axis (CX3CL1/CX3CR1)-NF-κB-NLRP3 and PI3K-AKT signaling pathways, regulate communications between neurons, neural stem cells and microglia ("the three-body problem"), and induce anti-inflammatory efficacy of microglia mitochondrial energy metabolic reprogramming in PD. The research uncovers the biodistribution, metabolic variances, and therapeutic mechanism of chiral NPs, providing deep insights into the nanobiological effects of chiral anti-inflammatory nanomedicines in PD therapy for future clinical transformation.
本研究先前报道,基于沸石咪唑酯骨架结构(ZIF)的手性纳米药物通过差异代谢和缓解神经炎症实现帕金森病(PD)治疗。然而,纳米药物缺乏整体手性和抗炎能力限制了对PD纳米生物学效应研究的进一步有效解决。在此,它巧妙地将手性金纳米团簇(AuNCs)负载到ZIF的内外表面,以实现同时提高复合纳米颗粒(NPs)的整体手性和抗炎活性的目的。不同手性NPs之间蛋白质冠层的组成存在显著差异,这阐明了手性介导的代谢差异和血脑屏障(BBB)穿越的机制。多组学和生化技术进一步揭示,手性NPs干扰趋化因子轴(CX3CL1/CX3CR1)-核因子κB(NF-κB)-NLRP3和磷脂酰肌醇-3-激酶(PI3K)-蛋白激酶B(AKT)信号通路,调节神经元、神经干细胞和小胶质细胞之间的通讯(“三体问题”),并诱导小胶质细胞线粒体能量代谢重编程在PD中的抗炎功效。该研究揭示了手性NPs的生物分布代谢差异和治疗机制,为手性抗炎纳米药物在PD治疗中的纳米生物学效应提供了深入见解,以供未来临床转化参考。